These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 26209985)

  • 1. The use of fenofibrate in the management of patients with diabetic retinopathy: an evidence-based review.
    Sharma N; Ooi JL; Ong J; Newman D
    Aust Fam Physician; 2015 Jun; 44(6):367-70. PubMed ID: 26209985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.
    Keech AC; Mitchell P; Summanen PA; O'Day J; Davis TM; Moffitt MS; Taskinen MR; Simes RJ; Tse D; Williamson E; Merrifield A; Laatikainen LT; d'Emden MC; Crimet DC; O'Connell RL; Colman PG;
    Lancet; 2007 Nov; 370(9600):1687-97. PubMed ID: 17988728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fenofibrate - a potential systemic treatment for diabetic retinopathy?
    Wong TY; Simó R; Mitchell P
    Am J Ophthalmol; 2012 Jul; 154(1):6-12. PubMed ID: 22709833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical management of diabetic retinopathy: fenofibrate and ACCORD Eye studies.
    Wright AD; Dodson PM
    Eye (Lond); 2011 Jul; 25(7):843-9. PubMed ID: 21436845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fenofibrate for Diabetic Retinopathy.
    Stewart S; Lois N
    Asia Pac J Ophthalmol (Phila); 2018; 7(6):422-426. PubMed ID: 30058790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetic retinopathy: treatment and prevention.
    Dodson PM
    Diab Vasc Dis Res; 2007 Sep; 4 Suppl 3():S9-S11. PubMed ID: 17935059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of micronized fenofibrate on microvascular complications of type 2 diabetes: a systematic review.
    Czupryniak L; Joshi SR; Gogtay JA; Lopez M
    Expert Opin Pharmacother; 2016 Aug; 17(11):1463-73. PubMed ID: 27267786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention and treatment of diabetic retinopathy: evidence from large, randomized trials. The emerging role of fenofibrate.
    Simó R; Hernández C
    Rev Recent Clin Trials; 2012 Feb; 7(1):71-80. PubMed ID: 21864248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study.
    Chew EY; Davis MD; Danis RP; Lovato JF; Perdue LH; Greven C; Genuth S; Goff DC; Leiter LA; Ismail-Beigi F; Ambrosius WT;
    Ophthalmology; 2014 Dec; 121(12):2443-51. PubMed ID: 25172198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Fenofibrate and Diabetic Retinopathy in Type 2 Diabetic Patients: A Population-Based Retrospective Cohort Study in Taiwan.
    Lin YC; Chen YC; Horng JT; Chen JM
    Medicina (Kaunas); 2020 Jul; 56(8):. PubMed ID: 32751875
    [No Abstract]   [Full Text] [Related]  

  • 11. Fenofibrate and diabetic retinopathy.
    Fagan XJ; Chong EW
    Clin Exp Ophthalmol; 2015; 43(4):297-9. PubMed ID: 26099043
    [No Abstract]   [Full Text] [Related]  

  • 12. Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study.
    Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Eye Study Group and the Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Study Group
    Diabetes Care; 2016 Jul; 39(7):1089-100. PubMed ID: 27289122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fenofibrate: a new treatment for diabetic retinopathy. Molecular mechanisms and future perspectives.
    Simó R; Roy S; Behar-Cohen F; Keech A; Mitchell P; Wong TY
    Curr Med Chem; 2013; 20(26):3258-66. PubMed ID: 23745548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of fenofibrate in clinical practice.
    Zambon A; Cusi K
    Diab Vasc Dis Res; 2007 Sep; 4 Suppl 3():S15-20. PubMed ID: 17935056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct effects of PPARα agonists on retinal inflammation and angiogenesis may explain how fenofibrate lowers risk of severe proliferative diabetic retinopathy.
    Abcouwer SF
    Diabetes; 2013 Jan; 62(1):36-8. PubMed ID: 23258912
    [No Abstract]   [Full Text] [Related]  

  • 16. Management of diabetic retinopathy: could lipid-lowering be a worthwhile treatment modality?
    Dodson PM
    Eye (Lond); 2009 May; 23(5):997-1003. PubMed ID: 19169236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-invited review: prevention of microvascular diabetic complications by fenofibrate: lessons from FIELD and ACCORD.
    Hermans MP
    Diab Vasc Dis Res; 2011 Jul; 8(3):180-9. PubMed ID: 21576195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fenofibrate for diabetic retinopathy.
    Simó R; Hernández C
    Lancet; 2007 Nov; 370(9600):1667-8. PubMed ID: 17988727
    [No Abstract]   [Full Text] [Related]  

  • 19. Fenofibrate and Diabetic Retinopathy.
    Knickelbein JE; Abbott AB; Chew EY
    Curr Diab Rep; 2016 Oct; 16(10):90. PubMed ID: 27525681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. More clinical lessons from the FIELD study.
    Fazio S
    Cardiovasc Drugs Ther; 2009 Jun; 23(3):235-41. PubMed ID: 19160032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.